Immune Design’s (IMDZ) CEO Carlos Paya on Q1 2017 Results – Earnings Call Transcript

Immune Design Corp. (NASDAQ:IMDZ)

Q1 2017 Earnings Conference Call

May 17, 2017 05:00 PM ET

Executives

Steve Brady – EVP, Strategy & Finance

Carlos Paya – CEO

Sergey Yurasov – SVP, Chief Medical Officer

Analysts

Boris Peaker – Cowen & Company

Rich Goss – Leerink Partners

Maury Raycroft – Jefferies

Operator

Good afternoon and thank you all for joining Immune Design’s First Quarter 2017 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only-mode. Following management’s remarks, we will hold a brief Question-and-Answer Session, and at that time, the lines will be open for you.

I would now like to turn the call over to Steve Brady, Executive Vice President, Strategy and Finance at Immune Design. Please go ahead, sir.

Steve Brady

Good afternoon and welcome to Immune Design’s First quarter results and corporate update conference call. Today, we’ll summarize the first quarter financial results and focus our comments on an update of our lead programs including the upcoming presentations at ASCO June meetings.

Copies of the due press releases across the wire today are available in the news section of our company’s website at immunedesign.com.

Today’s call is being recorded and will be available for telephonic replay at the same number as the conference call shortly after the call for five days as well as in the Investor Relations section of the company’s website for 30 days.

Joining me on the call today from Immune Design is Dr. Carlos Paya, President and Chief Executive Officer, and Dr. Sergey Yurasov, Senior Vice President and Chief Medical Officer at Immune Design.

Before we start I’d like to remind you that today’s call will include forward-looking statements based on current expectations. Forward-looking statements contained on this call will include, but are not limited to, statements about the design, progress, timing, scope and results of our clinical trials. The timing of the release of data from our…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *